RGEN
Repligen Corporation · Healthcare · Medical - Instruments & Supplies
Momentum-inputs (vergelijkbare managers):
breedte van houders +10.5% ·
aandelenstroom -4.9% ·
netto nieuwe posities +4.8%
· formule
Fragmentatie van eigendom: meer houders, kleiner totaalbelang
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 11.91K | $1.59M | n/a | n/a |
| Q2 2026 | 125 | +9 | 40.15M | $5.47B | +16 | −8 |
| Q1 2026 | 120 | -2 | 41.26M | $4.90B | +8 | −11 |
| Q4 2025 | 122 | -3 | 43.70M | $7.16B | +1 | −3 |
| Q3 2025 | 21 | +2 | 26.22M | $3.51B | +3 | −2 |
| Q2 2025 | 17 | +1 | 26.68M | $3.32B | +2 | −1 |
| Q1 2025 | 13 | +1 | 13.27M | $1.69B | +1 | n/a |
| Q4 2024 | 12 | 0 | 12.86M | $1.85B | +1 | −1 |
| Q3 2024 | 11 | -3 | 9.29M | $1.38B | n/a | −3 |
| Q2 2024 | 14 | n/a | 8.37M | $1.05B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 6.14M | +1.0% | $820.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 2 | The Vanguard Group ✦ (passief) | 5.04M | -0.7% | $674.26M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 3 | T. Rowe Price ✦ | 3.51M | -46.9% | $468.83M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 4 | Fidelity (FMR) ✦ | 2.69M | +66.8% | $359.73M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 5 | State Street Global Advisors ✦ (passief) | 1.80M | +11.0% | $240.81M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.68M | +58.5% | $225.20M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 1.44M | -24.7% | $192.58M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passief) | 1.03M | +5.3% | $138.03M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 817.06K | +16.5% | $109.22M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 546.90K | n/a | $73.11M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 11 | Morgan Stanley ✦ | 484.98K | n/a | $64.83M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 12 | D. E. Shaw & Co. ✦ | 249.93K | +4337.7% | $33.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 186.87K | +35.1% | $24.98M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Marshall Wace ✦ | 181.06K | +115.0% | $24.20M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 15 | Goldman Sachs Group ✦ | 120.50K | n/a | $16.11M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 16 | Renaissance Technologies ✦ | 109.40K | +65.0% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 94.86K | -69.7% | $12.68M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 43.21K | +83.4% | $5.78M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 33.62K | Nieuw | $4.49M | 0.0% | New | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 9.22K | Nieuw | $1.18M | 0.0% | New | 1 | SEC ↗ ×3 |
| 21 | Adage Capital Partners ✦ | 5.00K | Nieuw | $668,350 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $4.49M | 0.0% |
| AQR Capital Management | $1.18M | 0.0% |
| Adage Capital Partners | $668,350 | 0.0% |
Verlaten
| Norges Bank | $30.99M | was 0.0% |
| Wellington Management | $17.85M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 436 houders, 65.14M aandelen, $6.86B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 4.20K aand · $798,380
Officer, Director · 1.33K aand · $238,274
Officer, Director · 8.40K aand · $1.60M
Officer, Director · 4.54K aand · $862,980
Officer, Director · 5.43K aand · $976,680
Officer, Director · 3.04K aand · $503,506
Officer, Director · 5.43K aand · $976,680
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie